The Bronchodilator Test with Increasing Doses of Terbutaline in Chronic Obstructive Pulmonary Disease Patients
Heredia, J. L.
MetadataShow full item record
There is no uniform consensus on the dose of bronchodilator to be used in the bronchodilator test (BDT). The objective of the study was to determine the dose of inhaled terbutaline that can safely achieve a greater number of positive BDT in patients with chronic obstructive pulmonary disease (COPD).
The study was prospective and single blinded. One-hundred and fifty patients with stable COPD were included. Their mean (±SD) age was 67.4 (8.8) years. Their mean forced expiratory volume in the first second (FEV1) was 1.14 (0.48) l (41% of the predicted value). A baseline spirometry was performed and a second 20 min after the inhalation of placebo. Three consecutive doses of 500 g of inhaled terbutaline were administered and a new spirometry was performed after each one. A multivariate analysis based on the comparison of the repeated means was performed in order to analyse the spirometric changes achieved after the different doses of bronchodilator. The increase of FEV1 and forced vital capacity (FVC) with the two first doses of terbutaline was statistically significant; the increase of the peak expiratory flow (PEF) was significant after the three doses administered. The number of positive BDT were 40, 47 and 60 after each dose of terbutaline (P=0.004). The higher dose of terbutaline was more useful in identifying patients with significant bronchoreversibility and, moreover, was well tolerated. We suggest that this dose (1500 g) should be routinely used in performing the BDT
Is part ofPulmonary Pharmacology and Therapeutics, 2001, vol. 14, núm. 1, p. 61-65
European research projects
Showing items related by title, author, creator and subject.
Rodríguez-Carballeira, M.; Heredia, J. L.; Rué i Monné, Montserrat; Quintana, Salvador; Almagro, P. (Elsevier, 2007)The objective of the study was to evaluate the best method for interpreting the bronchodilator test (BDT). Five formulas for expressing the BDT results were analyzed and compared: changes experienced by maximum ...
C-reactive protein and other predictors of poor outcome in patients hospitalized with exacerbations of chronic obstructive pulmonary disease Ruiz González, Agustín; Lacasta García, José Daniel; Ibarz Escuer, Mercedes; Martínez Alonso, Montserrat; Falguera i Sacrest, Miquel; Porcel Pérez, José Manuel (Wiley, 2008)Background and objective: CRP is elevated in patients with acute exacerbations of COPD (AECOPD), but there is little information on whether this biomarker can help to identify adverse short-term clinical outcomes. Methods: ...
Risk of exacerbation in chronic obstructive pulmonary disease: a primary care retrospective cohort study Montserrat i Capdevila, Josep; Godoy i García, Pere; Marsal Mora, Josep Ramon; Barbé Illa, Ferran; Galván, Leonardo (BioMed Central, 2015)Background: The risk of exacerbation in chronic obstructive pulmonary disease (COPD) depends on the severity of disease and other less well known factors. Predictive models of exacerbation are more accurate than the forced ...